Chinese biopharma firm MabPlex nets $71m in Series B round

Chinese biopharma firm MabPlex nets $71m in Series B round

MabPlex International, a Chinese contract developer and manufacturer of biopharmaceuticals

MabPlex International, a Chinese contract developer and manufacturer of biopharmaceuticals, has garnered over 500 million yuan ($71 million) in a Series B round of financing led by private equity firms DT Capital Partners and Huajin Capital.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter